Navigation Links
Michael J. Fox Foundation Awards $2.9 Million for Two New Parkinson's Disease Clinical Trials
Date:1/12/2009

NEW YORK, Jan. 12 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research awarded about $2.9 million total for two clinical studies that will test drugs already approved in other disease indications for potential efficacy against Parkinson's disease. Because both drugs being tested are already known to be safe for humans, they hold potential to move swiftly toward regulatory approval for use in Parkinson's patients if they prove effective in PD.

One funded team will investigate the potential of simvastatin (marketed under the trade name Zocor), a drug currently used to treat high cholesterol, to reduce dyskinesias -- the disruptive, uncontrollable movements that are a side effect of long-term dopamine replacement. The other team will undertake a Phase 2 study to determine whether isradipine (marketed under the trade name Dynacirc), an approved high blood pressure medication, can rescue dopamine neurons from the degeneration seen in Parkinson's.

Although the drugs' current uses for cholesterol and blood pressure management might not seem relevant for PD, researchers found that the mechanisms by which each drug acts had unintended but beneficial effects on Parkinson's disease pathways in preclinical models of the disease.

The funding was awarded under the Foundation's Clinical Intervention Awards initiative, one of MJFF's three annually recurring Edmond J. Safra Core Programs for PD Research. The program supports novel or critical clinical intervention trials of promising therapeutic approaches that can significantly and fundamentally improve treatments for Parkinson's disease.

Funded projects are listed below. Detailed information, including grant abstracts and researcher bios, is available at www.michaeljfox.org.

A Randomized, Placebo-controlled, Multiple Crossover (n-of-1), Pilot trial of Simvastatin on the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients

Erwan Bezard, PhD, Universiy of Bordeaux, France, and Francois Tison, MD, PhD, Head of Movement Disorder Unit, University Hospital of Bordeaux, France

A Pilot Phase II Double-Blind, Placebo-Controlled, Dosage Finding and Tolerability Study of Isradipine as a Disease Modifying Agent in Patients with Early Parkinson's Disease

Tanya Simuni, MD, Parkinson's Disease and Movement Disorders Center, Northwestern University

About The Michael J. Fox Foundation

Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease within the decade through an aggressively funded research agenda. The Foundation has funded $135 million in research to date.


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
2. Michael J. Fox Foundation Commits Up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinsons Disease
3. New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials
4. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
5. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
6. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
7. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
8. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
9. Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee
10. Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinsons Disease Under Rapid Response Innovation Awards 2008
11. Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Lilly and Company (NYSE: LLY ) today ... at the 9 th Clinical Trials on Alzheimer,s ... meet the primary endpoint in the EXPEDITION3 clinical trial, ... dementia due to Alzheimer,s disease (AD), and Lilly will ... of mild dementia due to AD. ...
(Date:12/8/2016)... DUBLIN , Dec 8, 2016 Research ... Electrodes Market Analysis and Trends - Adhesion Type, Application, Usability - ... ... The Global Cardiology Electrodes Market is poised to grow at a ... prominent trends that the market is witnessing include advancements in extracellular ...
(Date:12/8/2016)... 8, 2016   TriNetX , the health ... Hospital signed a membership agreement to join ... of new cures. The TriNetX network ... million patients globally, biopharmaceutical companies and contract research ... protocol design, site selection, patient recruitment, and collaborative ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... The ... the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. ... safety. Only a few hospitals and facilities have earned this distinction. This is ...
(Date:12/8/2016)... ... December 08, 2016 , ... Russ ... announced the first national #QuackGivesBack campaign which supported local breast cancer organizations during ... franchise-wide Quack Gives Back initiative, and we’re very pleased with the ...
(Date:12/8/2016)... Pa. (PRWEB) , ... December 08, 2016 , ... ... Medicine Southern Chester County, a Property owned by an affiliate of Seavest, has ... square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was named ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... CURE Media ... centers and advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat ... the announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored to team ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont ... and attorneys from the firm’s global Life Sciences & Medical Technology Group have been ...
Breaking Medicine News(10 mins):